Lin28 Regulates Cancer Cell Stemness for Tumour Progression
Abstract
Tumours develop therapy resistance through complex mechanisms, one of which is that cancer stem cell (CSC) populations within the tumours present self-renewable capability and phenotypical plasticity to endure therapy-induced stress conditions and allow tumour progression to the therapy-resistant state. Developing therapeutic strategies to cope with CSCs requires a thorough understanding of the critical drivers and molecular mechanisms underlying the aforementioned processes. One such hub regulator of stemness is Lin28, an RNA-binding protein. Lin28 blocks the synthesis of let-7, a tumour-suppressor microRNA, and acts as a global regulator of cell differentiation and proliferation. Lin28also targets messenger RNAs and regulates protein translation. In this review, we explain the role of the Lin28/let-7 axis in establishing stemness, epithelial-to-mesenchymal transition, and glucose metabolism reprogramming. We also highlight the role of Lin28 in therapy-resistant prostate cancer progression and discuss the emergence of Lin28-targeted therapeutics and screening methods.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Sep 24, 2022
- Source ID
- 10.3390/cancers14194640
Entities
People
- Artem Cherkasov
- Mariia Radaeva
- Xuesen Dong
- Zhuohui Lin
Organizations
- Canadian Institutes of Health Research
- United States Department of Defense